Indaptus Therapeutics Files Prospectus Related To The Proposed Resale Of Up To 58,895,000 Shares Of Common Stock By Selling Stockholders

8-K filing — Indaptus Therapeutics, Inc. (INDP)

Filed: 2026-08-13 AccNo: 0001493152-26-037574 Size: 304 KB Item 2.02: Results of Operations and Financial Condition Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits

Indaptus Therapeutics Q2 EPS $(0.02) Beats $(1.57) Estimate

Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(1.57) by 98.73 percent. This is a 99.78 percent increase over losses of $(9.09) per share

Indaptus Therapeutics Files Prospectus Related To The Resale By The Selling Stockholders Of Up To 18.86M Shares Of Common Stock